PharmaFocus Today – Page 106 – media

Five innovative medical devices enter special review process

Recently, the Equipment Review Center of the National Medical Products Administration released the results of the special review application for innovative medical devices (No. 8 of 2024), intending to approve 5 innovative medical device projects to enter the special review process. 1. Human homologous recombination repair defect detection kit (high-throughput sequencing method): Xiamen Aide Biomedical Technology Co., Ltd Xiamen Aide Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as Aide Biotechnology) was established in 2008. It has long been deeply involved in the field of tumor gene testing, focusing on tumor drug co diagnosis. Relying on powerful bioinformatics algorithms, it has laid out detection reagents, software, and supporting instruments for various technology platforms, and provides detection services and drug clinical research services. In terms of products, Eide Biological Products has a wide range of products, which can detect the mutations of EGFR, KRAS, BRAF and other common genes, covering the disease ...
- Source: drugdu
- 167
- September 20, 2024
Cheng Yifan’s team reveals the activation and transmission mechanism of TGF – β signaling between cells

The following article is from the biological world, authored by the author Transforming growth factor beta (TGF – β) is a multifunctional cytokine that plays a critical role in processes such as development, immunity, cancer, and fibrosis. TGF – β has three different gene expression products (TGF – β 1, TGF – β 2, and TGF – β 3), all of which are expressed in an inactive (latent) form, namely L-TGF – β, and “activation” is crucial for its function. Most therapeutic strategies targeting TGF – β do not target specific latent and/or activation mechanisms, but rather inhibit the overall TGF – β signaling pathway and exhibit significant toxicity. A deeper understanding of latency and activation may contribute to the development of better TGF – β targeted therapeutic strategies. Traditionally, it is believed that mature TGF – β must physically dissociate from L-TGF – β 1 before signal transduction can ...
- Source: drugdu
- 132
- September 20, 2024
Rubicon WIPI Axis Regulates Extracellular Secretion Synthesis during Aging Process

picture Writing | Sister Xian Extracellular vesicles are important mediators of intercellular communication, consisting of small vesicles with diameters ranging from 30-150 nanometers. They can transport biomolecules such as proteins, lipids, and nucleic acids from one cell to another, thereby regulating the behavior of recipient cells. Due to their roles in various physiological and pathological processes, extracellular vesicles have become a hot topic in biomedical research. Studies have found that as age increases, the number and composition of circulating extracellular vesicles change, which may have significant impacts on the aging process. The changes in miRNA and other molecules in extracellular vesicles with age may affect cell function and tissue regeneration ability [1]. However, how extracellular vesicles change during aging and the molecular mechanisms behind these changes are currently not fully understood. The formation of extracellular vesicles is a complex multi-step process involving the endosomal pathway and the biological formation of ...
- Source: drugdu
- 200
- September 20, 2024
Novo Nordisk’s new anchor

In the first half of 2024, Novo Nordisk achieved revenue of 133.4 billion Danish kroner, a year-on-year increase of 24%, and its performance continued to grow. The increase in the volume of semaglutide is a key factor in the growth of performance. Ozempic, a semaglutide hypoglycemic injection, achieved revenue of 56.7 billion Danish kroner, Rybelsus, a semaglutide hypoglycemic oral agent, achieved revenue of 10.9 billion Danish kroner, and Wegovy, a semaglutide weight loss injection, achieved revenue of 21 billion Danish kroner. The total sales of semaglutide were 88.7 billion Danish kroner, a year-on-year increase of 43%, accounting for 2/3 of Novo Nordisk’s total revenue. While semaglutide is selling well around the world, Novo Nordisk is also constantly adjusting and optimizing its R&D strategy and business layout. By enriching its product portfolio, it will further strengthen its dominant position in the field of blood sugar and fat reduction. At the same ...
- Source: drugdu
- 129
- September 20, 2024
Pneumonia Vaccine Price War Erupted

A price war has erupted for pneumonia vaccines, with pharmaceutical companies attempting to exchange lower prices for market share. Recently, public resource trading center websites in several provinces, including Jilin and Jiangsu, have shown that Zhifei Biological’s wholly-owned subsidiary, Zhifei Lvzhu, has reduced the price of its 0.5ml, 23-valent pneumococcal polysaccharide vaccine from 298 yuan to 209 yuan, a decrease of nearly 30%. This follows a series of price cuts for other vaccines, such as the HPV and flu vaccines, marking yet another manufacturer proactively lowering vaccine supply prices. Will other manufacturers follow suit? Watson Bio recently disclosed in a research announcement that the price of its 23-valent pneumonia vaccine has remained stable since its market introduction. Currently, the nationwide average winning bid price is lower than the adjusted prices of its competitors, and the company hopes to maintain price stability for its related products. Zhifei Biological’s 23-valent pneumococcal polysaccharide ...
- Source: drugdu
- 132
- September 20, 2024
Metformin, new role discovered

On September 12, a research team from the Chinese Academy of Sciences published a result in the journal Cell, titled “Metformin decelerates aging clock in male monkeys.” After eight years of in-depth research, its findings were confirmed in primates. Metformin can significantly delay aging, especially protecting the brain cognitive function of elderly animals. This study found that the protective effect of metformin on primate aging does not depend on its traditional blood sugar and metabolic regulatory functions, but will reset the intrinsic program of cellular aging, thereby delaying cellular aging. Previously, in a research report titled “Metformin facilitates viral reservoir reactivation and their recognition by anti-HIV-1 envelope antibodies” published in the international magazine iScience, scientists from the University of Montreal and other institutions found through research that metformin may help HIV-infected people who are receiving treatment clear the reservoir of the virus in their bodies and eventually eliminate the virus. ...
- Source: drugdu
- 108
- September 20, 2024
How many drugs does Biotech need to sell to avoid losing money?

Looking around the world, biotech is a group with extremely high “metabolism”. According to statistics from GF Securities, since 1990, more than 600 biotech companies have IPOed on Nasdaq. However, as of June 30, 2020, only 12 biotechs have relatively stable income and positive cash flow. Extending the timeline, from the rise of the concept of biotech in the 1980s to the present, in 40 years, there are only a few who have entered the pharma camp by buying on their own. Why is it difficult for biotech to survive for a long time? This is determined by the business model. Compared with large pharmaceutical companies with average growth but strong certainty, biotech is a divergent innovation model, and the growth process is full of uncertainty. In other words, due to the high risk of R&D and the uncertainty of sales, most biotechs can’t run the business model at all, ...
- Source: drugdu
- 102
- September 20, 2024
Global medical device giant Jiadeno shuts down factories and lays off employees

Recently, according to The Irish Times, global medical device giant Gardiner has convened a meeting with all employees of its Tullamore factory in Ireland to announce its decision to close the Tullamore factory and cease production of a product. With the closure of the factory, 315 job positions will be cut, and up to 300 employees will face layoffs. According to public information, the Tullamore factory has a total of 315 employees. The first batch of employees will resign in March and April 2025, and the second batch of employees will resign in April and May 2026. Purchased for 43.4 billion yuan, net profit increased fivefold, still facing closure The Tullamore factory was established in 1982 and has undergone several rotations over the decades. Originally established by American disposable medical product manufacturer Sherwood Medical, the Tullamore factory was acquired by Tyco Healthcare in 1998, which is now the predecessor of ...
- Source: drugdu
- 129
- September 19, 2024
Andon Health has a tendency to invest in unmanned aerial vehicle medical transportation

According to the Qichacha APP, Tianjin Jiuyin Electronic Technology Co., Ltd. was recently established, with Li Kang as the legal representative and a registered capital of 500000 yuan. Its business scope includes: sales of satellite mobile communication terminals; Sales of navigation terminals; Sales of wearable smart devices; Sales of intelligent unmanned aerial vehicles, etc. Qichacha’s equity penetration shows that the company is wholly owned by Andon Health. In the field of medical applications, the “low altitude+medical rescue” unmanned aerial vehicle comprehensive solution has achieved normalized low altitude medical transportation services in multiple provinces and cities across the country. With the help of unmanned aerial vehicle technology, it innovates three key medical logistics scenarios: blood transportation, medical material distribution, and rapid response to emergency supplies. Will Jiu’an be involved in this direction in the future? Worth paying attention to. Has launched multiple wearable products, with asset management becoming one of its ...
- Source: drugdu
- 121
- September 19, 2024
Clinical study of innovative gene therapy drug LY-M003 injection launched

LY-M003 Disclaimer: Due to limited proficiency, errors are inevitable, or some information may not be timely. Please feel free to leave a message to indicate. This article only provides an introduction to medical and health-related drugs, and does not recommend treatment plans (if applicable); This article does not constitute any investment advice. Recently, a prospective, single center, open label, single arm, single dose clinical study evaluating the safety, tolerability, and efficacy of LY-M003 injection in the treatment of adult patients with Wilson’s disease was launched at the First Affiliated Hospital of Zhejiang University School of Medicine (hereinafter referred to as “Zhejiang First Hospital”). The project was led by Professor Yu Chaohui, the leader of the Gastroenterology Department, as the main researcher. LY-M003 injection is an innovative gene therapy drug developed by Lingyi (Hangzhou) Biotechnology Co., Ltd. (hereinafter referred to as “Lingyi Biotechnology”). The Department of Gastroenterology at Zhejiang First Hospital ...
- Source: drugdu
- 196
- September 19, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.